Sjöugren's syndrome influence of multiple hla‐d region alloantigens on clinical and serologic expression

Raymond W. Wilson, Thomas T. Provost, Wilma B. Bias, Elaine L. Alexander, Donald W. Edlow, Marc C. Hochberg, Mary Betty Stevens, Frank C. Arnett

Research output: Contribution to journalArticle

Abstract

The relationships of HLA—DR and the newer DS (second D locus) B cell alloantigens (MB and MT) to the clinical and serologic expression of primary and secondary forms of Sjögren's syndrome (SS) were examined in 102 patients (86 whites and 16 blacks). Although HLA‐DR3 was significantly increased in whites (25 of 50, 50%) and blacks (4 of 5, 80%) with primary SS compared with race‐matched normal controls, it was not appreciably elevated in those with systemic lupus erythematosus (SLE)‐SS, rheumatoid arthritis (RA)‐SS, or connective tissue disease‐SS. The MT2 specificity, however, was more strongly associated with primary SS (86% of whites and 100% of blacks) and also with SLE‐SS and RA‐SS compared with race‐matched normal controls. Furthermore, MT2 was significantly increased in SLE‐SS and RA‐SS when compared with non‐sicca SLE and RA controls. Although primary and secondary SS were most strongly associated with this DS specificity (MT2), the anti‐Ro (SS‐A) and anti‐La (SS‐B) antibody responses were more closely allied to DR antigens. HLA‐DR3 was increased in anti‐Ro positive patients, both whites and blacks, with primary SS (74%) and in total anti‐Ro positive subjects (54%) compared with their anti‐Ro negative counterparts (38% and 31%, respectively). Among DR3 negative patients, HLA‐DR2 correlated with anti‐Ro in both primary SS (83%) and in the total SS group (58%). Thus, 96% of Ro antibody positive patients with primary SS had DR3 and/or DR2, as did 80% of anti‐Ro positive subjects in all categories. Antibodies to La (SS‐B) correlated only with DR3 in primary SS and in the total group. These data suggest that MT2 is the strongest major histocompatibility complex determinant for primary and secondary SS. However, HLA‐DR3 and DR2 may mediate the Ro/La antibody responses that are characteristic of more severe disease. The clinical expression of Sjögren's syndrome appears to result from the complex genetic interplay of multiple HLA‐D region factors.

Original languageEnglish (US)
Pages (from-to)1245-1253
Number of pages9
JournalArthritis & Rheumatism
Volume27
Issue number11
DOIs
StatePublished - 1984

Fingerprint

Isoantigens
Systemic Lupus Erythematosus
Antibody Formation
Rheumatoid Arthritis
Major Histocompatibility Complex
Connective Tissue
B-Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Wilson, R. W., Provost, T. T., Bias, W. B., Alexander, E. L., Edlow, D. W., Hochberg, M. C., ... Arnett, F. C. (1984). Sjöugren's syndrome influence of multiple hla‐d region alloantigens on clinical and serologic expression. Arthritis & Rheumatism, 27(11), 1245-1253. https://doi.org/10.1002/art.1780271106

Sjöugren's syndrome influence of multiple hla‐d region alloantigens on clinical and serologic expression. / Wilson, Raymond W.; Provost, Thomas T.; Bias, Wilma B.; Alexander, Elaine L.; Edlow, Donald W.; Hochberg, Marc C.; Stevens, Mary Betty; Arnett, Frank C.

In: Arthritis & Rheumatism, Vol. 27, No. 11, 1984, p. 1245-1253.

Research output: Contribution to journalArticle

Wilson, RW, Provost, TT, Bias, WB, Alexander, EL, Edlow, DW, Hochberg, MC, Stevens, MB & Arnett, FC 1984, 'Sjöugren's syndrome influence of multiple hla‐d region alloantigens on clinical and serologic expression', Arthritis & Rheumatism, vol. 27, no. 11, pp. 1245-1253. https://doi.org/10.1002/art.1780271106
Wilson, Raymond W. ; Provost, Thomas T. ; Bias, Wilma B. ; Alexander, Elaine L. ; Edlow, Donald W. ; Hochberg, Marc C. ; Stevens, Mary Betty ; Arnett, Frank C. / Sjöugren's syndrome influence of multiple hla‐d region alloantigens on clinical and serologic expression. In: Arthritis & Rheumatism. 1984 ; Vol. 27, No. 11. pp. 1245-1253.
@article{32d6a488f4b44826b58cf1c9a761c179,
title = "Sj{\"o}ugren's syndrome influence of multiple hla‐d region alloantigens on clinical and serologic expression",
abstract = "The relationships of HLA—DR and the newer DS (second D locus) B cell alloantigens (MB and MT) to the clinical and serologic expression of primary and secondary forms of Sj{\"o}gren's syndrome (SS) were examined in 102 patients (86 whites and 16 blacks). Although HLA‐DR3 was significantly increased in whites (25 of 50, 50{\%}) and blacks (4 of 5, 80{\%}) with primary SS compared with race‐matched normal controls, it was not appreciably elevated in those with systemic lupus erythematosus (SLE)‐SS, rheumatoid arthritis (RA)‐SS, or connective tissue disease‐SS. The MT2 specificity, however, was more strongly associated with primary SS (86{\%} of whites and 100{\%} of blacks) and also with SLE‐SS and RA‐SS compared with race‐matched normal controls. Furthermore, MT2 was significantly increased in SLE‐SS and RA‐SS when compared with non‐sicca SLE and RA controls. Although primary and secondary SS were most strongly associated with this DS specificity (MT2), the anti‐Ro (SS‐A) and anti‐La (SS‐B) antibody responses were more closely allied to DR antigens. HLA‐DR3 was increased in anti‐Ro positive patients, both whites and blacks, with primary SS (74{\%}) and in total anti‐Ro positive subjects (54{\%}) compared with their anti‐Ro negative counterparts (38{\%} and 31{\%}, respectively). Among DR3 negative patients, HLA‐DR2 correlated with anti‐Ro in both primary SS (83{\%}) and in the total SS group (58{\%}). Thus, 96{\%} of Ro antibody positive patients with primary SS had DR3 and/or DR2, as did 80{\%} of anti‐Ro positive subjects in all categories. Antibodies to La (SS‐B) correlated only with DR3 in primary SS and in the total group. These data suggest that MT2 is the strongest major histocompatibility complex determinant for primary and secondary SS. However, HLA‐DR3 and DR2 may mediate the Ro/La antibody responses that are characteristic of more severe disease. The clinical expression of Sj{\"o}gren's syndrome appears to result from the complex genetic interplay of multiple HLA‐D region factors.",
author = "Wilson, {Raymond W.} and Provost, {Thomas T.} and Bias, {Wilma B.} and Alexander, {Elaine L.} and Edlow, {Donald W.} and Hochberg, {Marc C.} and Stevens, {Mary Betty} and Arnett, {Frank C.}",
year = "1984",
doi = "10.1002/art.1780271106",
language = "English (US)",
volume = "27",
pages = "1245--1253",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Sjöugren's syndrome influence of multiple hla‐d region alloantigens on clinical and serologic expression

AU - Wilson, Raymond W.

AU - Provost, Thomas T.

AU - Bias, Wilma B.

AU - Alexander, Elaine L.

AU - Edlow, Donald W.

AU - Hochberg, Marc C.

AU - Stevens, Mary Betty

AU - Arnett, Frank C.

PY - 1984

Y1 - 1984

N2 - The relationships of HLA—DR and the newer DS (second D locus) B cell alloantigens (MB and MT) to the clinical and serologic expression of primary and secondary forms of Sjögren's syndrome (SS) were examined in 102 patients (86 whites and 16 blacks). Although HLA‐DR3 was significantly increased in whites (25 of 50, 50%) and blacks (4 of 5, 80%) with primary SS compared with race‐matched normal controls, it was not appreciably elevated in those with systemic lupus erythematosus (SLE)‐SS, rheumatoid arthritis (RA)‐SS, or connective tissue disease‐SS. The MT2 specificity, however, was more strongly associated with primary SS (86% of whites and 100% of blacks) and also with SLE‐SS and RA‐SS compared with race‐matched normal controls. Furthermore, MT2 was significantly increased in SLE‐SS and RA‐SS when compared with non‐sicca SLE and RA controls. Although primary and secondary SS were most strongly associated with this DS specificity (MT2), the anti‐Ro (SS‐A) and anti‐La (SS‐B) antibody responses were more closely allied to DR antigens. HLA‐DR3 was increased in anti‐Ro positive patients, both whites and blacks, with primary SS (74%) and in total anti‐Ro positive subjects (54%) compared with their anti‐Ro negative counterparts (38% and 31%, respectively). Among DR3 negative patients, HLA‐DR2 correlated with anti‐Ro in both primary SS (83%) and in the total SS group (58%). Thus, 96% of Ro antibody positive patients with primary SS had DR3 and/or DR2, as did 80% of anti‐Ro positive subjects in all categories. Antibodies to La (SS‐B) correlated only with DR3 in primary SS and in the total group. These data suggest that MT2 is the strongest major histocompatibility complex determinant for primary and secondary SS. However, HLA‐DR3 and DR2 may mediate the Ro/La antibody responses that are characteristic of more severe disease. The clinical expression of Sjögren's syndrome appears to result from the complex genetic interplay of multiple HLA‐D region factors.

AB - The relationships of HLA—DR and the newer DS (second D locus) B cell alloantigens (MB and MT) to the clinical and serologic expression of primary and secondary forms of Sjögren's syndrome (SS) were examined in 102 patients (86 whites and 16 blacks). Although HLA‐DR3 was significantly increased in whites (25 of 50, 50%) and blacks (4 of 5, 80%) with primary SS compared with race‐matched normal controls, it was not appreciably elevated in those with systemic lupus erythematosus (SLE)‐SS, rheumatoid arthritis (RA)‐SS, or connective tissue disease‐SS. The MT2 specificity, however, was more strongly associated with primary SS (86% of whites and 100% of blacks) and also with SLE‐SS and RA‐SS compared with race‐matched normal controls. Furthermore, MT2 was significantly increased in SLE‐SS and RA‐SS when compared with non‐sicca SLE and RA controls. Although primary and secondary SS were most strongly associated with this DS specificity (MT2), the anti‐Ro (SS‐A) and anti‐La (SS‐B) antibody responses were more closely allied to DR antigens. HLA‐DR3 was increased in anti‐Ro positive patients, both whites and blacks, with primary SS (74%) and in total anti‐Ro positive subjects (54%) compared with their anti‐Ro negative counterparts (38% and 31%, respectively). Among DR3 negative patients, HLA‐DR2 correlated with anti‐Ro in both primary SS (83%) and in the total SS group (58%). Thus, 96% of Ro antibody positive patients with primary SS had DR3 and/or DR2, as did 80% of anti‐Ro positive subjects in all categories. Antibodies to La (SS‐B) correlated only with DR3 in primary SS and in the total group. These data suggest that MT2 is the strongest major histocompatibility complex determinant for primary and secondary SS. However, HLA‐DR3 and DR2 may mediate the Ro/La antibody responses that are characteristic of more severe disease. The clinical expression of Sjögren's syndrome appears to result from the complex genetic interplay of multiple HLA‐D region factors.

UR - http://www.scopus.com/inward/record.url?scp=0021645845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021645845&partnerID=8YFLogxK

U2 - 10.1002/art.1780271106

DO - 10.1002/art.1780271106

M3 - Article

C2 - 6208913

AN - SCOPUS:0021645845

VL - 27

SP - 1245

EP - 1253

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 11

ER -